ArticlePloS one2021
Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis.PloS one · 2024Pooled it
- Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis.American journal of hematology · 2026Article
- Postoperative Complications in Patients With Sickle Cell Disease After Total Shoulder Arthroplasty.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Article
- Multidimensional Predictors of Disease Severity and Health Outcomes in Patients with Sickle Cell Disease:Saudi medical journal · 2026Observational
- Retinal imaging and supervised learning predict hospitalizations and kidney and heart-lung damage in sickle cell disease.Blood advances · 2026Observational
- Radiomic Features Extracted from Magnetic Resonance Imaging to Identify Arteriopathy in a Humanized Mouse Model of Sickle Cell Anemia and Sickle Cell Trait.Annals of biomedical engineering · 2026Article
- Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.Neurology · 2026Article
- Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021.Annals of hematology · 2026Article
- Role of Menstrual Bleeding Assessments in Sickle Cell Clinics.JAMA network open · 2025Article
- Sex and genotype specificities of microvasculature and muscle remodeling in sub-Saharan sickle cell trait and disease.Blood advances · 2025Article
- Prevalence, risk factors, and demographic insights of sickle cell hepatopathy in Omani adolescents and adults: A retrospective analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- C-reactive protein and the menstrual cycle in females with sickle cell disease.Blood vessels, thrombosis & hemostasis · 2025Article
- The Prevalence and Predictors of Sickle Cell Anemia in the Saudi Arabia General Population: Findings from a Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- From early development to maturity: a phenotypic analysis of the Townes sickle cell disease mice.Biology open · 2025Article
- WHOQOL-BREF in Measuring Quality of Life Among Sickle Cell Disease Patients with Leg Ulcers.International journal of environmental research and public health · 2025Article
- Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Identifying distinct subgroups with severe pain in sickle cell disease: A cluster analysis of the GRNDaD multi-center registry.PloS one · 2025Article
- Adolescents' perspectives on non-pharmacological pain interventions for sickle cell crisis management: A population-based survey.PloS one · 2025Article
- Clinical Insights into Sickle Cell Disease: A Comprehensive Multicenter Retrospective Analysis of Clinical Characteristics and Outcomes Across Different Age Groups.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionSex-based clinical outcome differences in sickle cell disease (SCD) remain largely unknown despite evidence that female sex is associated with an increased lifespan. To better characterize sex-based differences in SCD, we assessed pain, treatment characteristics, laboratory measures and complications among males and females currently enrolled in the Sickle Cell Disease Implementation Consortium (SCDIC) registry.
methodsThe SCDIC consists of eight comprehensive SCD centers and one data coordinating center that received funding from the National Heart Lung and Blood Institute to improve outcomes for individuals with SCD. Eligibility criteria included: 15 to 45 years of age and a confirmed diagnosis of SCD. Self-report surveys were completed and data were also abstracted from the participants' medical records.
resultsA total of 2,124 participants were included (mean age: 27.8 years; 56% female). The majority had hemoglobin SS SCD genotype. Females had worse reports of pain severity (mean (SD) T-score 51.6 (9.6) vs 49.3 (10), p<0.001), more vaso-occlusive episodes (p = 0.01) and a higher occurrence of 3 or more hospital admissions in the past year (30.9% vs. 25.5, p = 0.03). On multivariable analysis, males had higher odds of acute chest syndrome (odds ratio (OR) 1.4, p = 0.002), cardiovascular (OR 1.70, p<0.001) and musculoskeletal (OR 1.33, p = 0.0034) complications and lower odds of depression (OR 0.77, p = 0.0381). Females had higher fetal hemoglobin levels with and without hydroxyurea use (9.6% vs 8.5%, p = 0.03 and 3% vs 2.2%, p = 0.0005, respectively).
conclusionOur data suggests that sex differences in clinical outcomes do occur among individuals with SCD. Future research needs to explore the mechanisms underlying these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.